Oxurion NV

LSE (EUR): Oxurion NV (0G99)

Last Price

0.00

Today's Change

0.00 (0.00%)

Day's Change

0.00 - 0.00

Trading Volume

2,000

Profile
0G99

Exchange:  London Stock Exchange London Stock Exchange

Currency:  EUR EUR

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Pascal Ghoson Mr. Pascal Ghoson

Full Time Employees:  20 20

IPO Date:  2008-08-06 2008-08-06

CIK: 

ISIN:  BE0003846632 BE0003846632

CUSIP: 

Beta:  0.58 0.58

Last Dividend:  0.00 0.00

Dcf Diff:  0.00 0.00

Dcf:  0.00 0.00

Description

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Address

Gaston Geenslaan 1,
Leuven, 3001, BE

32 1 675 13 10

http://www.oxurion.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment